Use of estradiol valerate with 17alpha -cyanomethyl-17-beta -hydroxyestra-4,9-diene-3-one for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. The combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate, a second phase consisting of 2 groups of daily dose units of the combination, where the first group contains 5 daily dose units and the second group contains 17 daily dose, and a third phase consisting of 2 daily dose units. Use of estradiol valerate with 17alpha -cyanomethyl-17-beta -hydroxyestra-4,9-diene-3-one (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding, in the form of oral contraceptives. The combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg, a second phase consisting of 2 groups of daily dose units, where the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate and 3 mg of dienogest, a third phase consisting of 2 daily dose units having 1 mg of estradiol valerate and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. The entire daily dose units of the multi-phase combination corresponds to 28 days. ACTIVITY : Contraceptive； Gynecological. MECHANISM OF ACTION : None given.
